Coronavirus (COVID-19)—UK life sciences tracker
Coronavirus (COVID-19)—UK life sciences tracker

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Coronavirus (COVID-19)—UK life sciences tracker
  • Research and development of medicines and vaccines
  • Clinical trials
  • Regulation of medical devices
  • Regulation of vaccines, medicinal products and blood
  • Post-authorisation vigilance of medicines and vaccines
  • Supply of vaccines, medicines and medical products
  • Actions on falsified and unlicensed medicines, off-label use of medical devices
  • mHealth and data protection

This Practice Note tracks the developments and updates on coronavirus (COVID-19) that relate to the life sciences sector in the UK. For coronavirus developments of interest to the life sciences sector in the EU, including those which may have applied to the UK until the end of the Brexit transition period, and internationally, see Practice Note: Coronavirus (COVID-19)—EU life sciences tracker.

Jump to

  1. Research and development of medicines and vaccines

  2. Clinical trials

  3. Regulation of medical devices

  4. Regulation of vaccines, medicinal products and blood

  5. Post-authorisation vigilance of medicines and vaccines

  6. Supply of vaccines, medicines and medical products

  7. Actions on falsified and unlicensed medicines, off-label use of medical devices

  8. mHealth and data protection

For a discussion on:

  1. the impact of the coronavirus pandemic on the UK and EU regulatory frameworks, see Practice Note: Coronavirus (COVID-19)—regulatory implications for the UK and European life sciences industry

  2. what life sciences companies should take into account when protecting and sharing intellectual property (IP) with third parties in the fight against the coronavirus pandemic in order to avoid potentially adverse unintended consequences, see Practice Note: Coronavirus (COVID-19)—intellectual property implications for life sciences companies

  3. a vision of the future for life sciences industry after the coronavirus pandemic, see News Analysis: A vision of the future after Coronavirus (COVID-19)

  4. the use of artificial intelligence (AI) by researchers, governments and health organisations as a tool to

Popular documents